Boston Biomedical to Highlight Data for Cancer Stemness Inhibitor Napabucasin in Patients with Colorectal Cancer at 2017 ASCO GI
CAMBRIDGE, Mass., Jan. 18, 2017 /PRNewswire/ -- Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, will feature data from two clinical studies for its lead investigational compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, held from January 19-21, in San Francisco.
Napabucasin is an orally-administered investigational agent designed to inhibit cancer stemness pathways by targeting STAT3.i Cancer stem cells (CSCs) possess the property of stemness – the ability to self-renew and differentiate into heterogeneous cancer cells. This allows the CSCs to act like seeds, causing a patient's cancer to relapse or spread within the body.ii,iii In preclinical studies, the STAT3 pathway was identified as an important pathway for maintaining cancer stemness.
Data from the two studies will be presented as poster presentations on January 21. The studies evaluate anti-cancer activity of napabucasin in combination with FOLFIRI with and without bevacizumab in patients with metastatic colorectal cancer (CRC), including treatment-naïve patients and patients previously exposed to FOLFIRI regardless of pSTAT3 status, and safety and anti-cancer activity of napabucasin in combination with panitumumab in patients with K-ras wild type metastatic colorectal cancer (mCRC).
Planned data posters include:
Saturday, January 21, from 7:00 AM – 7:55 AM and 12:30 PM – 2:00 PM PST; Moscone West Building
- Abstract #593: Cancer Stemness Inhibition and Chemosensitization: Phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (bev) administered to colorectal cancer (CRC) patients (pts)
- Bendell J1, O'Neil BH2, Starodub A3, Jonker D4, Halfdanarson TR5, Edenfield J6, El-Rayes, B7, Hubbard J8, Pitot H8, Hobday T8, Li Y-Z9, Gao Y9, Grothey A8, Borodyansky L9, and Li CJ9
- 1. Sarah Cannon Cancer Research Program, Nashville, TN; 2. IU Health University Hospital, Indianapolis, IN; 3. IU Goshen Health Center, Goshen, IN; 4. The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; 5. Mayo Clinic, Scottsdale, AZ; 6. Institute for Translational Oncology Research, Greenville, SC; 7. The Winship Cancer Institute of Emory University, Atlanta, GA; 8. Mayo Clinic, Rochester, MN; 9. Boston Biomedical, Inc., Cambridge, MA.
- Abstract #677: BBI608-224: A Phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) administered with panitumumab in K-ras wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC)
- Larson TG1, Ciombor K2, Becerra CHR1, Hubbard JM3, Edenfield WJ4, Shao S5, Grothey A3, Walsh E7, Borodyansky L7, Ortuzar W7, Khan W7, Xu B7, Li W1, Li Y7, Li CJ7 and Bekaii-Saab T6
- 1. US Oncology Research, TOPS Phase I Program; 2. Ohio State University Wexner Medical Center, Columbus, OH; 3. Mayo Clinic, Rochester, MN; 4. Institute for Translational Oncology Research, Greenville Hospital System/University Medical Center, Greenville, SC; 5. Northwest Cancer Specialist, Portland OR; 6. Mayo Clinic, Scottsdale AZ; 7. Boston Biomedical, Inc., Cambridge, MA
About Napabucasin
Napabucasin is an orally-administered investigational agent designed to inhibit cancer stemness pathways by targeting STAT3.i
Napabucasin is currently being investigated in multiple Phase III studies, including gastric and gastroesophageal junction (GEJ) (NCT02178956), colorectal (NCT02753127) and pancreatic cancer (NCT0299373). It is also being investigated in earlier phases in multiple solid and hematologic malignancies, including tumors of the lung, liver, pancreas and brain. In 2016, the U.S. Food and Drug Administration granted Orphan Drug Designation for napabucasin in gastric/GEJ and pancreatic cancer.
More information on napabucasin and ongoing clinical trials can be found at www.BostonBiomedical.com.
About Boston Biomedical
Boston Biomedical, Inc. (Founder, President, CEO and CMO: Chiang J. Li, M.D. FACP) was founded in November 2006 and is wholly owned by Sumitomo Dainippon Pharma Co., Ltd. Boston Biomedical's mission is to develop the next generation of cancer therapeutics by creating drugs designed to target cancer stemness pathways. Boston Biomedical's innovation in drug discovery has received a number of recognitions and awards in the United States, including the Frost & Sullivan 2010 North American Drug Discovery Technology Innovation of the Year Award, the National Cancer Institute (NCI) cancer stem cell initiative grant award in 2010, and the 2011 Biotech Pioneer Award at the Alexandria Oncology Summit. The company also received the "Company To Watch" award in the 10th Annual Team Massachusetts Economic Impact Awards in 2013. Boston Biomedical is headquartered in Cambridge, Massachusetts, USA.
Additional information about the company and its product pipeline can be found at www.BostonBiomedical.com.
Disclaimer Regarding Forward-Looking Statements
The forward-looking statements in this press release are based on management's assumptions and beliefs in light of information presently available, and involve both known and unknown risks and uncertainties. Any forward looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.
For general inquiries:
Boston Biomedical
617-674-6800
For media inquiries:
Sara Baker
CHAMBERLAIN PR
212- 849-9474
[email protected]
i Li Y, Rogoff HA et al. PNAS. 112(6):1839-44, 2015.
ii Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med. 2009;15(9):1010-1012.
iii Ajani JA, Song S, Hochster HS, Steinberg IB. Cancer stem cells: the promise and the potential. Semin Oncol. 2015;42(suppl 1):S3-S17.
SOURCE Boston Biomedical Pharma, Inc.
Share this article